Print Page | Close Window Welcome to Array BioPharma Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company and currently expects significant progress toward generating data to support our upcoming Phase 3 / pivotal trial decisions. Novartis began a Phase 3 trial evaluating Array-invented MEK162 in patients with NRAS-mutant melanoma in July 2013 and expects to begin a Phase 3 trial in patients with BRAF-mutant melanoma in 2013. In addition, Array began a Phase 3 trial evaluating MEK162 in patients with low-grade serous ovarian cancer under the license agreement with Novartis in June 2013. AstraZeneca began a pivotal trial with Array-invented selumetinib in patients with thyroid cancer in May 2013 and expects to begin a Phase 3 trial in patients with non-small cell lung cancer in 2013. Three other Array-invented drugs are also approaching Phase 3 or pivotal trial decisions which are expected by the end of 2013. These include Array's wholly-owned drugs, ARRY-520 and ARRY-614, and one partnered program, danoprevir (with InterMune/Roche). Latest News and Press Releases: 9/4/2013 Array Biopharma To Present at the Morgan Stanley Global Healthcare Conference and the Stifel Healthcare Conference 8/7/2013 Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2013 7/29/2013 Array BioPharma And Celgene Corporation Announce Strategic global R&D Collaboration To Advance Medical Innovation To Benefit Patients 7/29/2013 Array BioPharma To Report Financial Results For The Fourth Quarter And Full Year Of Fiscal 2013 On August 7, 2013